Ready for the challenge: navigating the evolving landscape of GLP-1s for pediatric obesity treatment

The landscape for obesity treatment is undergoing a rapid and unprecedented evolution. The past year has seen a proliferation of TV commercials, search engine ads, social media influencers, celebrities, and medical professionals touting the weight loss and health improvement benefits of glucagon-like peptide-1 receptor agonists (GLP-1s). These medications, which include liraglutide (Saxenda) and semaglutide (Wegovy), are now FDA-approved for obesity management in youth ages 12 and older, and recent trial results suggest impending availability for children as young as six years of age (Fox et al., 2025). Consumer demand has been tremendous, with a nearly 600% increase in prescriptions for adolescents between 2020 and 2023 (Lee et al., 2024). In currently approved formulations, GLP-1s are injectable medications; Saxenda is taken daily, while Wegovy is administered weekly.1 These medications mimic the actions of metabolic hormones that stimulate insulin production and inhibit glucagon production, which, in turn, lowers blood sugar levels. GLP-1s also promote weight loss by acting on the brain’s satiety centers to decrease appetite and by slowing the emptying of food from the stomach into the small intestine, which extends feelings of fullness. While biologically efficient, these medications are not a standalone solution. Fundamentally, the effectiveness of GLP-1s is contingent upon behavioral lifestyle management (Rogers et al., 2025).